![Loh Chin Siew](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Loh Chin Siew
Anciens postes connus de Loh Chin Siew
Sociétés | Poste | Début | Fin |
---|---|---|---|
ProTherapeutics Pte Ltd.
![]() ProTherapeutics Pte Ltd. BiotechnologyHealth Technology ProTherapeutics Pte Ltd. develops new drugs from proteins. It also offers bioactive peptides, which are derived from snake venom toxins and human proteins for tumor regression, macular degeneration, diabetic retinopathy, anti-hypertension, anti-inflammation, hypolocomotion effect, and clot initiation. The company was founded by Ruowen Ge, Peter Wong Tsun Hon, and R. Manjunatha Kini in April 2005 and is headquartered in Singapore. | Directeur/Membre du Conseil | - | - |
Singapore Economic Development Board | Corporate Officer/Principal | - | - |
Bio*One Capital Pte Ltd.
![]() Bio*One Capital Pte Ltd. Investment ManagersFinance Bio*One Capital Pte Ltd (Bio*One Capital) is a venture capital subsidiary of EDB Investments Pte Ltd founded in 1991. The firm is headquartered in Singapore. | Private Equity Investor | - | - |
Formation de Loh Chin Siew
INSEAD | Masters Business Admin |
University of Bristol | Undergraduate Degree |
Statistiques
Internationale
Singapour | 4 |
France | 2 |
Royaume-Uni | 2 |
Opérationnelle
Private Equity Investor | 1 |
Director/Board Member | 1 |
Masters Business Admin | 1 |
Sectorielle
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Bio*One Capital Pte Ltd.
![]() Bio*One Capital Pte Ltd. Investment ManagersFinance Bio*One Capital Pte Ltd (Bio*One Capital) is a venture capital subsidiary of EDB Investments Pte Ltd founded in 1991. The firm is headquartered in Singapore. | Finance |
ProTherapeutics Pte Ltd.
![]() ProTherapeutics Pte Ltd. BiotechnologyHealth Technology ProTherapeutics Pte Ltd. develops new drugs from proteins. It also offers bioactive peptides, which are derived from snake venom toxins and human proteins for tumor regression, macular degeneration, diabetic retinopathy, anti-hypertension, anti-inflammation, hypolocomotion effect, and clot initiation. The company was founded by Ruowen Ge, Peter Wong Tsun Hon, and R. Manjunatha Kini in April 2005 and is headquartered in Singapore. | Health Technology |
Singapore Economic Development Board | Government |
- Bourse
- Insiders
- Loh Chin Siew
- Expérience